Sarepta's DMD trial halted in U.K. on safety signal

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it halted dosing at U.K. study sites in the Phase III ESSENCE trial evaluating golodirsen

Read the full 204 word article

User Sign In